Minesh Mehta

List of Publications by Year
in descending order

550 papers	52,697 citations	1269 109 h-index	1829 209 g-index
759 all docs	759 docs citations	759 times ranked	35670 citing authors

#	Article	IF	Citations
1	A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma. New England Journal of Medicine, 2014, 370, 699-708.	30.1	2,351
2	Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet, The, 2004, 363, 1665-1672.	12.1	2,284
3	Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases. Journal of Clinical Oncology, 2012, 30, 419-425.	15.4	1,238
4	Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402. Journal of Clinical Oncology, 2013, 31, 337-343.	15.4	998
5	Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial. Journal of Clinical Oncology, 2014, 32, 3810-3816.	15.4	928
6	A New Prognostic Index and Comparison to Three Other Indices for Patients With Brain Metastases: An Analysis of 1,960 Patients in the RTOG Database. International Journal of Radiation Oncology Biology Physics, 2008, 70, 510-514.	0.8	925
7	Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 Patients. International Journal of Radiation Oncology Biology Physics, 2010, 77, 655-661.	0.8	889
8	Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial. Journal of Clinical Oncology, 2013, 31, 4085-4091.	15.4	866
9	Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. New England Journal of Medicine, 2016, 374, 1344-1355.	30.1	853
10	Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro-Oncology, 2013, 15, 1429-1437.	1.2	776
11	Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncology, The, 2015, 16, e270-e278.	10.8	771
12	Correlation of O⁶-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity. Journal of Clinical Oncology, 2008, 26, 4189-4199.	15.4	732
13	Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology, 2006, 24, 2707-2714.	15.4	681
14	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology, 2020, 22, 1073-1113.	1.2	652
15	Estimating Survival in Patients With Lung Cancer and Brain Metastases. JAMA Oncology, 2017, 3, 827.	7.3	568
16	Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol. International Journal of Radiation Oncology Biology Physics, 2004, 60, 853-860.	0.8	538
17	Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. Journal of Clinical Oncology, 2020, 38, 1019-1029.	15.4	535
18	Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial. Journal of Clinical Oncology, 2004, 22, 157-165.	15.4	529

#	Article	IF	Citations
19	Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model. Journal of Clinical Oncology, 2006, 24, 5711-5715.	15.4	524
20	A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. International Journal of Radiation Oncology Biology Physics, 1996, 35, 27-35.	0.8	519
21	A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. International Journal of Radiation Oncology Biology Physics, 2002, 53, 519-526.	0.8	515
22	American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guideline for the Performance of Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2010, 76, 326-332.	0.8	484
23	The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2010, 96, 45-68.	3.0	457
24	Image guidance for precise conformal radiotherapy. International Journal of Radiation Oncology Biology Physics, 2003, 56, 89-105.	0.8	447
25	Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases. Journal of Clinical Oncology, 2003, 21, 2529-2536.	15.4	441
26	Whole-Brain Radiotherapy in the Management of Brain Metastasis. Journal of Clinical Oncology, 2006, 24, 1295-1304.	15.4	436
27	Tomotherapy. Seminars in Radiation Oncology, 1999, 9, 108-117.	2.3	391
28	Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-Oncology, 2008, 10, 162-170.	1.2	369
29	The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2010, 96, 33-43.	3.0	369
30	Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation ofIDH. Journal of Clinical Oncology, 2014, 32, 783-790.	15.4	363
31	An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLRâ€“Dependent Pathway. Cancer Discovery, 2011, 1, 442-456.	14.2	357
32	A multigene predictor of outcome in glioblastoma. Neuro-Oncology, 2010, 12, 49-57.	1.2	343
33	Current Management of Brain Metastases, With a Focus on Systemic Options. Journal of Clinical Oncology, 2005, 23, 6207-6219.	15.4	339
34	Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2012, 82, 2111-2117.	0.8	331
35	The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. International Journal of Radiation Oncology Biology Physics, 2005, 63, 37-46.	0.8	327
36	Why avoid the hippocampus? A comprehensive review. Radiotherapy and Oncology, 2010, 97, 370-376.	0.6	323

#	Article	IF	Citations
37	Hippocampal Dosimetry Predicts Neurocognitive Function Impairment After Fractionated Stereotactic Radiotherapy for Benign or Low-Grade Adult Brain Tumors. International Journal of Radiation Oncology Biology Physics, 2013, 85, 348-354.	0.8	315
38	Hippocampal-Sparing Whole-Brain Radiotherapy: A â€œHow-Toâ€•Technique Using Helical Tomotherapy and Linear Acceleratorâ€“Based Intensity-Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1244-1252.	0.8	313
39	Differential Sensitivity of Glioma- versus Lung Cancerâ€“Specific EGFR Mutations to EGFR Kinase Inhibitors. Cancer Discovery, 2012, 2, 458-471.	14.2	311
40	Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802. Journal of Clinical Oncology, 2012, 30, 3065-3070.	15.4	308
41	Regression After Whole-Brain Radiation Therapy for Brain Metastases Correlates With Survival and Improved Neurocognitive Function. Journal of Clinical Oncology, 2007, 25, 1260-1266.	15.4	303
42	The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2010, 96, 103-114.	3.0	291
43	EGFR Signaling Through an Akt-SREBP-1â€“Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy. Science Signaling, 2009, 2, ra82.	5.1	287
44	The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2010, 96, 17-32.	3.0	280
45	A challenge to traditional radiation oncology. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1241-1256.	0.8	276
46	Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. Journal of Clinical Oncology, 2020, 38, 3773-3784.	15.4	264
47	Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. International Journal of Radiation Oncology Biology Physics, 2001, 51, 426-434.	0.8	262
48	Relationship Between Neurocognitive Function and Quality of Life After Whole-Brain Radiotherapy in Patients With Brain Metastasis. International Journal of Radiation Oncology Biology Physics, 2008, 71, 64-70.	0.8	260
49	A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-Oncology, 2010, 12, 95-103.	1.2	258
50	A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer and 1 to 3 Brain Metastases: Radiation Therapy Oncology Group 0320. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1312-1318.	0.8	257
51	The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy. International Journal of Radiation Oncology Biology Physics, 2005, 61, 779-788.	0.8	255
52	A new approach to dose escalation in nonâ€“small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2001, 49, 23-33.	0.8	241
53	Updates in the management of brain metastases. Neuro-Oncology, 2016, 18, 1043-1065.	1.2	220
54	Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, 623-630.	0.8	210

#	Article	IF	Citations
55	Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study. Journal of Clinical Oncology, 2011, 29, 2689-2695.	15.4	206
56	A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study1. Neuro-Oncology, 2006, 8, 189-193.	1.2	203
57	A cost-effectiveness and cost-utility analysis of radiosurgery vs. resection for single-brain metastases. International Journal of Radiation Oncology Biology Physics, 1997, 39, 445-454.	0.8	196
58	American Society for Therapeutic Radiology and Oncology* and American College of Radiology Practice Guideline for the Performance of Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1026-1032.	0.8	195
59	Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro-Oncology, 2010, 12, 855-861.	1.2	188
60	MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro-Oncology, 2019, 21, 167-178.	1.2	188
61	Phase II Trial of Radiosurgery for One to Three Newly Diagnosed Brain Metastases From Renal Cell Carcinoma, Melanoma, and Sarcoma: An Eastern Cooperative Oncology Group Study (E 6397). Journal of Clinical Oncology, 2005, 23, 8870-8876.	15.4	178
62	Whole Brain Radiotherapy With Hippocampal Avoidance and Simultaneously Integrated Brain Metastases Boost: A Planning Study. International Journal of Radiation Oncology Biology Physics, 2007, 69, 589-597.	0.8	178
63	Distribution of Brain Metastases in Relation to the Hippocampus: Implications for Neurocognitive Functional Preservation. International Journal of Radiation Oncology Biology Physics, 2007, 68, 971-977.	0.8	176
64	Radiosurgery in the initial management of malignant gliomas: Survival comparison with the RTOG recursive partitioning analysis. International Journal of Radiation Oncology Biology Physics, 1995, 32, 931-941.	0.8	175
65	Hippocampal Dosimetry Predicts Neurocognitive Function Impairment After Fractionated Stereotactic Radiotherapy for Benign or Low-Grade Adult Brain Tumors. International Journal of Radiation Oncology Biology Physics, 2012, 83, e487-e493.	0.8	175
66	Presentation, patterns of care, and survival in patients with brain metastases. Cancer, 2011, 117, 2505-2512.	4.1	173
67	Outcome of Children With Metastatic Medulloblastoma Treated With Carboplatin During Craniospinal Radiotherapy: A Children's Oncology Group Phase I/II Study. Journal of Clinical Oncology, 2012, 30, 2648-2653.	15.4	173
68	Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: Safety profile for RTOG 0933. Radiotherapy and Oncology, 2010, 95, 327-331.	0.6	171
69	Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathologica, 2012, 123, 205-222.	7.9	169
70	A systematic review of the cost and costâ€effectiveness studies of proton radiotherapy. Cancer, 2016, 122, 1483-1501.	4.1	168
71	Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. Journal of Clinical Oncology, 2016, 34, 731-739.	15.4	168
72	Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. Journal of Neuro-Oncology, 2010, 96, 211-217.	3.0	167

#	Article	IF	Citations
73	Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). International Journal of Radiation Oncology Biology Physics, 2017, 99, 812-816.	0.8	167
74	The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. International Journal of Radiation Oncology Biology Physics, 2005, 63, 47-55.	0.8	163
75	Motexafin Gadolinium Combined With Prompt Whole Brain Radiotherapy Prolongs Time to Neurologic Progression in Nonâ€“Small-Cell Lung Cancer Patients With Brain Metastases: Results of a Phase III Trial. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1069-1076.	0.8	162
76	Secondary Analysis of RTOG 9508, a Phase 3 Randomized Trial of Whole-Brain Radiation Therapy Versus WBRT Plus Stereotactic Radiosurgery in Patients With 1-3 Brain Metastases; Poststratified by the Graded Prognostic Assessment (GPA). International Journal of Radiation Oncology Biology Physics, 2014, 90, 526-531.	0.8	158
77	Helical Tomotherapy: An Innovative Technology and Approach to Radiation Therapy. Technology in Cancer Research and Treatment, 2002, 1, 311-316.	1.9	151
78	Phase II Evaluation of Temozolomide and 13-cis-Retinoic Acid for the Treatment of Recurrent and Progressive Malignant Glioma: A North American Brain Tumor Consortium Study. Journal of Clinical Oncology, 2003, 21, 2305-2311.	15.4	151
79	Phase III Study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction Chemotherapy Followed by Either Standard Thoracic Radiotherapy or Hyperfractionated Accelerated Radiotherapy for Patients With Unresectable Stage IIIA and B Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 3760-3767.	15.4	151
80	Phase II Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Either Receiving or Not Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study. Journal of Clinical Oncology, 2006, 24, 3651-3656.	15.4	151
81	Dosimetric comparison of left-sided whole breast irradiation with 3DCRT, forward-planned IMRT, inverse-planned IMRT, helical tomotherapy, and topotherapy. Radiotherapy and Oncology, 2011, 100, 241-246.	0.6	150
82	Association ofMGMTPromoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide. JAMA Oncology, 2018, 4, 1405.	7.3	149
83	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro-Oncology, 2017, 19, 625-635.	1.2	148
84	Stereotactic radiosurgery for glioblastoma multiforme: Report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. International Journal of Radiation Oncology Biology Physics, 1994, 30, 541-549.	0.8	146
85	Integral radiation dose to normal structures with conformal external beam radiation. International Journal of Radiation Oncology Biology Physics, 2006, 64, 962-967.	0.8	145
86	RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1206-1211.	0.8	143
87	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro-Oncology, 2014, 16, 567-578.	1.2	143
88	The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2010, 96, 71-83.	3.0	142
89	Lead-In Phase to Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation for Patients With Brain Metastases: Centralized Assessment of Magnetic Resonance Imaging, Neurocognitive, and Neurologic End Points. Journal of Clinical Oncology, 2002, 20, 3445-3453.	15.4	141
90	The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. Journal of Neuro-Oncology, 2013, 112, 467-472.	3.0	141

#	Article	IF	Citations
91	Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. Journal of Neuro-Oncology, 2019, 145, 97-105.	3.0	139
92	The utility of megavoltage computed tomography images from a helical tomotherapy system for setup verification purposes. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1639-1644.	0.8	137
93	Phase 2 Study of Temozolomide-Based Chemoradiation Therapy for High-Risk Low-Grade Gliomas: Preliminary Results of Radiation Therapy Oncology Group 0424. International Journal of Radiation Oncology Biology Physics, 2015, 91, 497-504.	0.8	136
94	Dose-Limiting Toxicity After Hypofractionated Dose-Escalated Radiotherapy in Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2013, 31, 4343-4348.	15.4	134
95	Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf	1.2	133
96	Phase III Study Comparing Three Cycles of Infusional Carmustine and Cisplatin Followed by Radiation Therapy With Radiation Therapy and Concurrent Carmustine in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme: Eastern Cooperative Oncology Group Trial 2394. Journal of Clinical Oncology, 2003, 21, 1485-1491.	15.4	131
97	High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539. International Journal of Radiation Oncology Biology Physics, 2020, 106, 790-799.	0.8	129
98	The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2010, 96, 97-102.	3.0	128
99	The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2010, 96, 85-96.	3.0	127
100	A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro-Oncology, 2012, 14, 910-918.	1.2	127
101	Multicenter Phase Ib/II Trial of the Radiation Enhancer Motexafin Gadolinium in Patients With Brain Metastases. Journal of Clinical Oncology, 2001, 19, 2074-2083.	15.4	126
102	Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. Journal of Clinical Oncology, 2020, 38, 3407-3417.	15.4	126
103	Anaplastic Oligodendroglial Tumors: Refining the Correlation among Histopathology, 1p 19q Deletion and Clinical Outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathology, 2008, 18, 360-369.	4.2	125
104	Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. Journal of Clinical Oncology, 2016, 34, 1620-1625.	15.4	123
105	The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. International Journal of Radiation Oncology Biology Physics, 2004, 58, 927-931.	0.8	121
106	Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncology, The, 2013, 14, e407-e416.	10.8	121
107	Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro-Oncology, 2015, 17, 992-998.	1.2	120
108	Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. Journal of Neuro-Oncology, 2012, 106, 147-153.	3.0	117

#	Article	IF	Citations
109	Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncology, The, 2013, 14, e396-e406.	10.8	116
110	Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. Journal of Clinical Oncology, 2017, 35, 361-369.	15.4	115
111	A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. Neuro-Oncology, 2018, 20, 666-673.	1.2	115
112	Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma. Journal of Clinical Oncology, 2013, 31, 4076-4084.	15.4	114
113	Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro-Oncology, 2017, 19, 1119-1126.	1.2	113
114	Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment. Current Cancer Therapy Reviews, 2011, 7, 319-327.	0.4	111
115	An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Neuro-Oncology, 2017, 19, now208.	1.2	111
116	Tumor volume changes on serial imaging with megavoltage CT for nonâ€“small-cell lung cancer during intensity-modulated radiotherapy: How reliable, consistent, and meaningful is the effect?. International Journal of Radiation Oncology Biology Physics, 2006, 66, 135-141.	0.8	110
117	Short Delay in Initiation of Radiotherapy May Not Affect Outcome of Patients With Glioblastoma: A Secondary Analysis From the Radiation Therapy Oncology Group Database. Journal of Clinical Oncology, 2009, 27, 733-739.	15.4	108
118	Clinical trial end points for high-grade glioma: the evolving landscape. Neuro-Oncology, 2011, 13, 353-361.	1.2	106
119	Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?. Neuro-Oncology, 2011, 13, 1118-1124.	1.2	102
120	RSR13 Plus Cranial Radiation Therapy in Patients With Brain Metastases: Comparison With the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. Journal of Clinical Oncology, 2003, 21, 2364-2371.	15.4	101
121	Management of brain metastases. Seminars in Oncology, 2004, 31, 693-701.	2.3	100
122	Minimization of small bowel volume within treatment fields utilizing customized â€œbelly boardsâ€• International Journal of Radiation Oncology Biology Physics, 1990, 19, 469-476.	0.8	99
123	Effect of the Addition of Chemotherapy to Radiotherapy on Cognitive Function in Patients With Low-Grade Glioma: Secondary Analysis of RTOG 98-02. Journal of Clinical Oncology, 2014, 32, 535-541.	15.4	99
124	Bevacizumab for Newly Diagnosed Glioblastoma. New England Journal of Medicine, 2014, 370, 2048-2049.	30.1	98
125	Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539. Neuro-Oncology, 2016, 18, 565-574.	1.2	98
126	Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro-Oncology, 2012, 14, 1511-1518.	1.2	96

#	Article	IF	Citations
127	Improvement, Clinical Course, and Quality of Life After Palliative Radiotherapy for Recurrent Glioblastoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 300-305.	1.3	95
128	Phase I Three-Dimensional Conformal Radiation Dose Escalation Study in Newly Diagnosed Glioblastoma: Radiation Therapy Oncology Group Trial 98-03. International Journal of Radiation Oncology Biology Physics, 2009, 73, 699-708.	0.8	95
129	Pseudoprogression after glioma therapy: a comprehensive review. Expert Review of Neurotherapeutics, 2013, 13, 389-403.	2.8	94
130	Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and nonâ€“small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2007, 67, 187-195.	0.8	93
131	Prognostic indices for brain metastases â€“ usefulness and challenges. Radiation Oncology, 2009, 4, 10.	2.7	93
132	A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1422-1428.	0.8	92
133	A Phase III Study of Conventional Radiation Therapy Plus Thalidomide Versus Conventional Radiation Therapy for Multiple Brain Metastases (RTOG 0118). International Journal of Radiation Oncology Biology Physics, 2008, 71, 79-86.	0.8	92
134	A Comprehensive Assessment by Tumor Site of Patient Setup Using Daily MVCT Imaging From More Than 3,800 Helical Tomotherapy Treatments. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1260-1269.	0.8	91
135	New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. Neuro-Oncology, 2013, 15, 1568-1579.	1.2	91
136	American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for the Performance of Stereotactic Radiosurgery (SRS). American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 310-315.	1.3	91
137	Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today. International Journal of Radiation Oncology Biology Physics, 2020, 107, 334-343.	0.8	90
138	A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants. Cancer, 2001, 91, 417-422.	4.1	89
139	Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study. Journal of Neuro-Oncology, 2015, 122, 409-417.	3.0	89
140	Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. Radiotherapy and Oncology, 2017, 123, 376-381.	0.6	89
141	Localized 2DJ-resolved H MR spectroscopy of human brain tumorsin vivo. Journal of Magnetic Resonance Imaging, 1996, 6, 453-459.	3.6	88
142	Prospective Evaluation of Quality of Life and Neurocognitive Effects in Patients With Multiple Brain Metastases Receiving Whole-Brain Radiotherapy With or Without Thalidomide on Radiation Therapy Oncology Group (RTOG) Trial 0118. International Journal of Radiation Oncology Biology Physics, 2008, 71, 71-78.	0.8	86
143	The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2016, 96, 406-413.	0.8	86
144	Clinical Implementation of Adaptive Helical Tomotherapy: A Unique Approach to Image-Guided Intensity Modulated Radiotherapy. Technology in Cancer Research and Treatment, 2006, 5, 465-479.	1.9	85

#	Article	IF	Citations
145	Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era. JAMA Oncology, 2017, 3, 784.	7.3	84
146	Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. Neuro-Oncology, 2021, 23, 881-893.	1.2	84
147	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. Clinical Cancer Research, 2022, 28, 594-602.	7.2	84
148	Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 97, 362-371.	0.8	82
149	Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of Radiation Therapy Oncology Group trial BR-0018. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1346-1352.	0.8	81
150	Reduction in Radiation Dose to Lung and Other Normal Tissues Using Helical Tomotherapy to Treat Lung Cancer, in Comparison to Conventional Field Arrangements. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 70-78.	1.3	80
151	Phase II Study of Fenretinide (NSC 374551) in Adults With Recurrent Malignant Gliomas: A North American Brain Tumor Consortium Study. Journal of Clinical Oncology, 2004, 22, 4282-4289.	15.4	80
152	Inguinofemoral radiation of N0,N1 vulvar cancer may be equivalent to lymphadenectomy if proper radiation technique is used. International Journal of Radiation Oncology Biology Physics, 1993, 27, 963-967.	0.8	78
153	Randomized Phase III Study of Thoracic Radiation in Combination With Paclitaxel and Carboplatin With or Without Thalidomide in Patients With Stage III Nonâ€“Small-Cell Lung Cancer: The ECOG 3598 Study. Journal of Clinical Oncology, 2012, 30, 616-622.	15.4	75
154	Neurocognitive and Functional Assessment of Patients With Brain Metastases. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 273-279.	1.3	71
155	Tomotherapy and Other Innovative IMRT Delivery Systems. Seminars in Radiation Oncology, 2006, 16, 199-208.	2.3	71
156	Feasibility report of image guided stereotactic body radiotherapy (IG-SBRT) with tomotherapy for early stage medically inoperable lung cancer using extreme hypofractionation. Acta OncolÃ³gica, 2006, 45, 890-896.	1.9	71
157	Phase II Study of Phenylacetate in Patients With Recurrent Malignant Glioma: A North American Brain Tumor Consortium Report. Journal of Clinical Oncology, 1999, 17, 984-984.	15.4	70
158	Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. Neuro-Oncology, 2004, 6, 44-54.	1.2	70
159	Recent advances in managing brain metastasis. F1000Research, 2018, 7, 1772.	1.6	70
160	Meningeal hemangiopericytoma: defining the role for radiation therapy. Journal of Neuro-Oncology, 1992, 14, 277-87.	3.0	69
161	Development of a Unique Phantom to Assess the Geometric Accuracy of Magnetic Resonance Imaging for Stereotactic Localization. Neurosurgery, 1999, 45, 1423-1431.	1.3	69
162	A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. Journal of Neuro-Oncology, 2009, 91, 183-189.	3.0	69

#	Article	IF	Citations
163	NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. Journal of Clinical Oncology, 2023, 41, 1285-1295.	15.4	69
164	Current Therapeutic Paradigms in Glioblastoma. Reviews on Recent Clinical Trials, 2010, 5, 14-27.	0.9	67
165	Caloric restriction coupled with radiation decreases metastatic burden in triple negative breast cancer. Cell Cycle, 2016, 15, 2265-2274.	2.8	67
166	Low-Grade Glioma Radiotherapy Treatment and Trials. Neurosurgery Clinics of North America, 2019, 30, 111-118.	1.8	67
167	PROOF OF PRINCIPLE OF OCULAR SPARING IN DOGS WITH SINONASAL TUMORS TREATED WITH INTENSITY-MODULATED RADIATION THERAPY. Veterinary Radiology and Ultrasound, 2010, 51, 561-570.	1.1	66
168	Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study. Journal of Neuro-Oncology, 2017, 131, 105-115.	3.0	66
169	Dose Escalated, Hypofractionated Radiotherapy Using Helical Tomotherapy for Inoperable Non-Small Cell Lung Cancer: Preliminary Results of a Risk-Stratified Phase I Dose Escalation Study. Technology in Cancer Research and Treatment, 2008, 7, 441-447.	1.9	65
170	Current Treatment Strategies for Brain Metastasis and Complications From Therapeutic Techniques. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 398-407.	1.3	65
171	Establishing Evidence-Based Indications for Proton Therapy: An Overview of Current Clinical Trials. International Journal of Radiation Oncology Biology Physics, 2017, 97, 228-235.	0.8	64
172	Single institution experience treating 104 vestibular schwannomas with fractionated stereotactic radiation therapy or stereotactic radiosurgery. Journal of Neuro-Oncology, 2014, 116, 187-193.	3.0	63
173	NRG brain tumor specialists consensus guidelines for glioblastoma contouring. Journal of Neuro-Oncology, 2019, 143, 157-166.	3.0	63
174	Phase I Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Taking Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study. Journal of Clinical Oncology, 2005, 23, 6647-6656.	15.4	61
175	Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Neuro-Oncology, 2020, 22, 94-102.	1.2	61
176	Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept. Clinical Cancer Research, 2011, 17, 4872-4881.	7.2	60
177	The Prognostic Value of BRAF , C-KIT , and NRAS Mutations in Melanoma Patients With Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1069-1077.	0.8	60
178	NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma. Journal of Neuro-Oncology, 2017, 131, 193-199.	3.0	60
179	Endobronchial irradiation for malignant airway obstruction. International Journal of Radiation Oncology Biology Physics, 1989, 17, 847-851.	0.8	59
180	Early changes in tumor metabolism after treatment: The effects of stereotactic radiotherapy. International Journal of Radiation Oncology Biology Physics, 1991, 20, 1053-1060.	0.8	59

#	Article	IF	Citations
181	Are gadolinium contrast agents suitable for gadolinium neutron capture therapy?. Neurological Research, 2005, 27, 387-398.	1.4	59
182	Outcome and prognostic factors for children with supratentorial primitive neuroectodermal tumors treated with carboplatin during radiotherapy: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2015, 62, 776-783.	1.6	59
183	A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. Journal of Neuro-Oncology, 2016, 126, 309-316.	3.0	59
184	Crimean-Congo haemorrhagic fever in India. Lancet, The, 2011, 378, 372.	12.1	58
185	Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review. Journal of Gastrointestinal Oncology, 2016, 7, 644-664.	1.4	58
186	Clinical Outcomes and Toxicity of Proton Radiotherapy for Breast Cancer. Clinical Breast Cancer, 2016, 16, 145-154.	2.6	58
187	Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neuro-Oncology, 2004, 6, 33-37.	1.2	57
188	Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition. Acta Neuropathologica, 2020, 139, 1071-1088.	7.9	57
189	Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neuro-Oncology, 2023, 25, 339-350.	1.2	56
190	Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials. Neuro-Oncology, 2004, 6, 96-103.	1.2	55
191	Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial. Cancer Chemotherapy and Pharmacology, 2008, 62, 227-233.	2.4	55
192	Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro-Oncology, 2009, 11, 167-175.	1.2	55
193	RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2013, 86, 880-884.	0.8	55
194	Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. International Journal of Radiation Oncology Biology Physics, 2018, 100, 38-44.	0.8	55
195	Treatment of arteriovenous malformations with stereotactic radiosurgery employing both magnetic resonance angiography and standard angiography as a database. International Journal of Radiation Oncology Biology Physics, 1993, 25, 309-313.	0.8	54
196	Comparison of linac based fractionated stereotactic radiotherapy and tomotherapy treatment plans for skull-base tumors. Radiotherapy and Oncology, 2006, 78, 313-321.	0.6	54
197	Molecular Profiling in Nonâ€“Small Cell Lung Cancer: A Step Toward Personalized Medicine. Archives of Pathology and Laboratory Medicine, 2013, 137, 481-491.	2.5	54
198	Proton therapy for paediatric CNS tumours â€” improving treatment-related outcomes. Nature Reviews Neurology, 2016, 12, 334-345.	10.0	54

#	Article	IF	Citations
199	Consensus guidelines for high dose rate remote brachytherapy in cervical, endometrial, and endobronchial tumors*. International Journal of Radiation Oncology Biology Physics, 1993, 27, 1241-1244.	0.8	53
200	Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-00211. Neuro-Oncology, 2006, 8, 47-52.	1.2	53
201	Prognostic and predictive factors in patients with brain metastases from solid tumors: A review of published nomograms. Critical Reviews in Oncology/Hematology, 2018, 126, 13-18.	4.5	53
202	Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. Neuro-Oncology, 2020, 22, 1359-1367.	1.2	53
203	Preoperative Vs Postoperative Radiosurgery For Resected Brain Metastases: A Review. Neurosurgery, 2019, 84, 19-29.	1.3	52
204	Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-Î² for supratentorial glioblastoma: Results of RTOG 9710. International Journal of Radiation Oncology Biology Physics, 2006, 66, 818-824.	0.8	51
205	The Evolving Role of Tumor Treating Fields in Managing Glioblastoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 191-196.	1.3	51
206	Current radiosurgery practice: results of an astro survey. International Journal of Radiation Oncology Biology Physics, 1994, 28, 523-526.	0.8	50
207	Monte Carlo and convolution dosimetry for stereotactic radiosurgery. International Journal of Radiation Oncology Biology Physics, 1990, 19, 1027-1035.	0.8	49
208	Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma. Cancer, 2004, 100, 1712-1716.	4.1	49
209	Randomized Phase II Trial of High-Dose Melatonin and Radiation Therapy for RPA Class 2 Patients With Brain Metastases (RTOG 0119). International Journal of Radiation Oncology Biology Physics, 2007, 68, 852-857.	0.8	49
210	Therapeutic advances for glioblastoma multiforme: Current status and future prospects. Current Oncology Reports, 2007, 9, 66-70.	4.1	49
211	The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. Journal of Neuro-Oncology, 2010, 96, 115-142.	3.0	49
212	Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool. Neuro-Oncology, 2018, 20, 1652-1660.	1.2	49
213	The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation. Journal of Neuro-Oncology, 1996, 30, 1-6.	3.0	48
214	Megavoltage Computed Tomography Imaging: A Potential Tool to Guide and Improve the Delivery of Thoracic Radiation Therapy. Clinical Lung Cancer, 2004, 5, 303-306.	2.7	48
215	Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: A Children's Oncology Group phase I study. Neuro-Oncology, 2008, 10, 752-758.	1.2	48
216	Cognition and Quality of Life After Chemotherapy Plus Radiotherapy (RT) vs. RT for Pure and Mixed Anaplastic Oligodendrogliomas: Radiation Therapy Oncology Group Trial 9402. International Journal of Radiation Oncology Biology Physics, 2010, 77, 662-669.	0.8	48

#	Article	IF	Citations
217	Linear Accelerator Radiosurgery for Trigeminal Neuralgia. Neurosurgery, 2005, 57, 1193-1200.	1.3	47
218	A Phase II Study of Preradiotherapy Chemotherapy Followed by Hyperfractionated Radiotherapy for Newly Diagnosed High-Risk Medulloblastoma/Primitive Neuroectodermal Tumor: A Report From the Children's Oncology Group (CCG 9931). International Journal of Radiation Oncology Biology Physics, 2009, 74, 1006-1011.	0.8	47
219	A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro-Oncology, 2010, 12, 87-94.	1.2	47
220	RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. Journal of Clinical Oncology, 2023, 41, 5187-5199.	15.4	47
221	Effect of Endobronchial Radiation Therapy on Malignant Bronchial Obstruction. Chest, 1990, 97, 662-665.	0.9	46
222	A three-dimensional volume visualization package applied to stereotactic radiosurgery treatment planning. International Journal of Radiation Oncology Biology Physics, 1991, 21, 491-500.	0.8	46
223	A phase II trial of thymidine and carboplatin for recurrent malignant glioma: A North American Brain Tumor Consortium Study. Neuro-Oncology, 2002, 4, 109-114.	1.2	46
224	Angiogenic Blockade and Radiotherapy in Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2010, 78, 188-193.	0.8	46
225	Primary Treatment Options for High-Risk/Medically Inoperable Early Stage NSCLC Patients. Clinical Lung Cancer, 2015, 16, 413-430.	2.7	46
226	Atypical meningioma: Randomized trials are required to resolve contradictory retrospective results regarding the role of adjuvant radiotherapy. Journal of Cancer Research and Therapeutics, 2015, 11, 59.	0.9	46
227	Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncology, The, 2018, 19, e33-e42.	10.8	46
228	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459.		46
229	Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors. International Journal of Radiation Oncology Biology Physics, 2022, 114, 60-74.	0.8	46
230	Optically guided intensity modulated radiotherapy. Radiotherapy and Oncology, 2001, 61, 33-44.	0.6	45
231	Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: Report from the Radiation Therapy Oncology Group. International Journal of Radiation Oncology Biology Physics, 2005, 62, 318-327.	0.8	45
232	A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas. Cancer, 2005, 104, 1968-1974.	4.1	45
233	Stereotactic Radiosurgery for Treatment of Brain Metastases. Journal of Oncology Practice, 2016, 12, 703-712.	3.0	45
234	The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group. Radiation Oncology, 2008, 3, 32.	2.7	44

#	Article	IF	Citations
235	Age as an independent prognostic factor in patients with glioblastoma: a radiation therapy oncology group and American College of Surgeons National Cancer Data Base comparison. Journal of Neuro-Oncology, 2011, 104, 351-356.	3.0	43
236	Helical Tomotherapy as a Means of Delivering Accelerated Partial Breast Irradiation. Technology in Cancer Research and Treatment, 2004, 3, 639-646.	1.9	41
237	Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. Neuro-Oncology, 2017, 19, now236.	1.2	41
238	Barriers to accrual and enrollment in brain tumor trials. Neuro-Oncology, 2019, 21, 1100-1117.	1.2	41
239	Current Strategies in Whole-brain Radiation Therapy for Brain Metastases. Neurosurgery, 2005, 57, S4-33.	1.3	40
240	Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03. Journal of Neuro-Oncology, 2009, 95, 247-257.	3.0	40
241	Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy. Journal of the National Cancer Institute, 2013, 105, 686-693.	6.4	40
242	A Retrospective Review of Nodal Treatment for Vulvar Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1993, 16, 38-42.	1.3	39
243	The effect of M-stage on patterns of failure in posterior fossa primitive neuroectodermal tumors treated on CCG-921: A phase III study in a high-risk patient population. International Journal of Radiation Oncology Biology Physics, 1997, 38, 469-475.	0.8	39
244	Neurocognitive sequelae of cancer treatment. Neurology, 2002, 59, 8-10.	1.1	39
245	A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: First report of the Children's Cancer Group-0952. Neuro-Oncology, 2003, 5, 8-13.	1.2	39
246	Results of the Phase I Dose-Escalating Study of Motexafin Gadolinium With Standard Radiotherapy in Patients With Glioblastoma Multiforme. International Journal of Radiation Oncology Biology Physics, 2007, 69, 831-838.	0.8	39
247	Glioblastoma: Radiation treatment margins, how small is large enough?. Practical Radiation Oncology, 2016, 6, 298-305.	2.1	39
248	Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. Cancer Discovery, 2023, 13, 2370-2393.	14.2	39
249	Therapeutic management of metastatic brain tumors. Critical Reviews in Oncology/Hematology, 2007, 61, 70-78.	4.5	38
250	Temozolomide, sirolimus and chloroquine is a new therapeutic combination that synergizes to disrupt lysosomal function and cholesterol homeostasis in GBM cells. Oncotarget, 2018, 9, 6883-6896.	2.1	38
251	Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. International Journal of Radiation Oncology Biology Physics, 2001, 50, 1199-1206.	0.8	37
252	Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas. Cancer, 2005, 104, 1281-1287.	4.1	37

#	Article	IF	Citations
253	Reirradiation for Locoregionally Recurrent Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 70-76.	1.3	37
254	Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. Journal of Clinical Oncology, 2022, 40, 2539-2545.	15.4	36
255	Radiosurgery for Brain Metastases. Neurosurgery Clinics of North America, 1999, 10, 337-350.	1.8	35
256	CogState computerized memory tests in patients with brain metastases: secondary endpoint results of NRG Oncology RTOG 0933. Journal of Neuro-Oncology, 2016, 126, 327-336.	3.0	35
257	Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424. International Journal of Radiation Oncology Biology Physics, 2020, 107, 720-725.	0.8	35
258	Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme. Journal of Neuro-Oncology, 1993, 15, 57-66.	3.0	34
259	Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database. Neuro-Oncology, 2018, 20, 966-974.	1.2	34
260	The Impact of Mid-Treatment MRI on Defining Boost Volumes in the Radiation Treatment of Glioblastoma Multiforme. Technology in Cancer Research and Treatment, 2004, 3, 303-307.	1.9	33
261	Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults. Journal of Neuro-Oncology, 2008, 89, 313-337.	3.0	33
262	The physical, biologic, and clinical basis of radiosurgery. Current Problems in Cancer, 1995, 19, 270-328.	2.1	32
263	A phase II study of preradiation chemotherapy followed by external beam radiotherapy for the treatment of patients with newly diagnosed glioblastoma multiforme: an Eastern Cooperative Oncology Group study (E2393). Journal of Neuro-Oncology, 2000, 47, 145-152.	3.0	32
264	Gentlemen (and Ladies), Choose your Weapons: Gamma Knife vs. Linear Accelerator Radiosurgery. Technology in Cancer Research and Treatment, 2003, 2, 79-85.	1.9	32
265	Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?. Critical Reviews in Oncology/Hematology, 2006, 60, 99-111.	4.5	32
266	The Impact of Hybrid PET-CT Scan on Overall Oncologic Management, with a Focus on Radiotherapy Planning: A Prospective, Blinded Study. Technology in Cancer Research and Treatment, 2009, 8, 149-158.	1.9	32
267	Intensity-Modulated Radiotherapy Might Increase Pneumonitis Risk Relative to Three-Dimensional Conformal Radiotherapy in Patients Receiving Combined Chemotherapy and Radiotherapy: A Modeling Study of Dose Dumping. International Journal of Radiation Oncology Biology Physics, 2011, 80, 893-899.	0.8	32
268	Neural stem cells, the subventricular zone and radiotherapy: implications for treating glioblastoma. Journal of Neuro-Oncology, 2016, 128, 207-216.	3.0	32
269	Stereotactic Radiosurgery for Glioblastoma. Cureus, 2015, 7, e413.	0.5	32
270	Radiation induced thyroid neoplasms 1920 to 1987: A vanishing problem?. International Journal of Radiation Oncology Biology Physics, 1989, 16, 1471-1475.	0.8	31

#	Article	IF	Citations
271	O 6-Benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. Neuro-Oncology, 2004, 6, 28-32.	1.2	31
272	Patterns of failure in supratentorial primitive neuroectodermal tumors treated in Children's Cancer Group Study 921, a phase III combined modality study. International Journal of Radiation Oncology Biology Physics, 2004, 60, 204-213.	0.8	31
273	Megavoltage Computed Tomography. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 617-623.	1.3	31
274	A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients. International Journal of Radiation Oncology Biology Physics, 2017, 98, 820-828.	0.8	31
275	Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. Journal of Neuro-Oncology, 2019, 144, 205-210.	3.0	31
276	NRG/RTOG 1122: A phase 2, doubleâ€blinded, placeboâ€controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer, 2020, 126, 2821-2828.	4.1	31
277	Motexafin gadolinium in the treatment of brain metastases. Expert Opinion on Pharmacotherapy, 2007, 8, 351-359.	1.9	30
278	The Dandelion Effect: Treat the Whole Lawn or Weed Selectively?. Journal of Clinical Oncology, 2011, 29, 121-124.	15.4	30
279	The role of radiation in treating glioblastoma: here to stay. Journal of Neuro-Oncology, 2017, 134, 479-485.	3.0	30
280	Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium. Neuro-Oncology, 2008, 10, 631-642.	1.2	29
281	A Phase I Trial of Tipifarnib With Radiation Therapy, With and Without Temozolomide, for Patients With Newly Diagnosed Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1422-1427.	0.8	29
282	Real-Time Pretreatment Review Limits Unacceptable Deviations on a Cooperative Group Radiation Therapy Technique Trial: Quality Assurance Results of RTOG 0933. International Journal of Radiation Oncology Biology Physics, 2015, 91, 564-570.	0.8	27
283	Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. Journal of Neuro-Oncology, 2015, 124, 413-420.	3.0	27
284	Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. Journal of Neuro-Oncology, 2018, 136, 79-86.	3.0	27
285	Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer. Journal of Gastrointestinal Oncology, 2018, 9, 687-693.	1.4	27
286	Consensus statement on stereotactic radiosurgery quality improvement. International Journal of Radiation Oncology Biology Physics, 1994, 28, 527-530.	0.8	26
287	Estimated radiation pneumonitis risk after photon versus proton therapy alone or combined with chemotherapy for lung cancer. Acta OncolÃ³gica, 2011, 50, 772-776.	1.9	26
288	Intracranial relapse rates and patterns, and survival trends following post-resection cavity radiosurgery for patients with single intracranial metastases. Journal of Neuro-Oncology, 2012, 108, 141-146.	3.0	26

#	Article	IF	Citations
289	Estimating survival in patients with gastrointestinal cancers and brain metastases: An update of the graded prognostic assessment for gastrointestinal cancers (GI-GPA). Clinical and Translational Radiation Oncology, 2019, 18, 39-45.	1.8	26
290	Cavernous sinus cranial neuropathies: is there a dose-response relationship following radiosurgery?. International Journal of Radiation Oncology Biology Physics, 1993, 27, 477-480.	0.8	25
291	Pilot and Safety Trial of Carboplatin, Paclitaxel, and Thalidomide in Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2000, 2, 48-52.	2.7	25
292	Fractionated Stereotactic Radiotherapy: A Short Review. Technology in Cancer Research and Treatment, 2002, 1, 153-172.	1.9	25
293	Advances in Radiation Therapy for Brain Tumors. Neurologic Clinics, 2007, 25, 1005-1033.	1.9	25
294	Breathing-Synchronized Delivery: A Potential Four-Dimensional Tomotherapy Treatment Technique. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1572-1578.	0.8	25
295	A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas. Journal of Neuro-Oncology, 2017, 133, 589-594.	3.0	25
296	Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneous. Radiation Oncology, 2019, 14, 33.	2.7	25
297	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Neuro-Oncology, 2020, 22, 601-612.	1.2	25
298	Stereotactic Irradiation. American Journal of Clinical Oncology: Cancer Clinical Trials, 1999, 22, 143-146.	1.3	25
299	Radiation Therapy for Leptomeningeal Cancer. , 2005, 125, 147-158.		24
300	It Is Time to Reevaluate the Management of Patients With Brain Metastases. Neurosurgery, 2014, 75, 1-9.	1.3	24
301	Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2018, 101, 845-853.	0.8	24
302	Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia. Frontiers in Oncology, 2020, 10, 254.	2.9	24
303	Craniospinal treatment with the patient supine. Medical Dosimetry, 2003, 28, 35-38.	0.8	23
304	Motexafin gadolinium: a novel radiosensitizer for brain tumors. Expert Review of Anticancer Therapy, 2007, 7, 785-794.	2.6	23
305	Opportunities for clinical research in meningioma. Journal of Neuro-Oncology, 2010, 99, 417-422.	3.0	23
306	The controversy surrounding the use of whole-brain radiotherapy in brain metastases patients. Neuro-Oncology, 2015, 17, 919-923.	1.2	23

#	Article	IF	Citations
307	Proton radiotherapy for gynecologic neoplasms. Acta OncolÃ³gica, 2016, 55, 1257-1265.	1.9	23
308	Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients. Archives of Virology, 2016, 161, 3161-3169.	1.9	23
309	Thoracic volume radiation sparing following endobronchial brachytherapy: A quantitative analysis. International Journal of Radiation Oncology Biology Physics, 1993, 25, 703-707.	0.8	22
310	Models Support Prophylactic Cranial Irradiation. Journal of Clinical Oncology, 2006, 24, 3524-3526.	15.4	22
311	Dose Coverage Beyond the Gross Tumor Volume for Various Stereotactic Body Radiotherapy Planning Techniques Reporting Similar Control Rates for Stage I Nonâ€“Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1597-1603.	0.8	22
312	Fractionated radiotherapy for intracranial meningiomas. Journal of Neuro-Oncology, 2010, 99, 349-356.	3.0	22
313	It Is Time to Include Patients With Brain Tumors in Phase I Trials in Oncology. Journal of Clinical Oncology, 2011, 29, 3211-3213.	15.4	22
314	Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation. Journal of Neuro-Oncology, 2017, 134, 331-338.	3.0	22
315	Treatment recommendations for elderly patients with newly diagnosed glioblastoma lack worldwide consensus. Journal of Neuro-Oncology, 2018, 140, 421-426.	3.0	22
316	Updates in the management of intradural spinal cord tumors: a radiation oncology focus. Neuro-Oncology, 2019, 21, 707-718.	1.2	22
317	Brain Metastasis and Response to Ado-Trastuzumab Emtansine: A Case Report and Literature Review. Clinical Breast Cancer, 2015, 15, e163-e166.	2.6	21
318	Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery, 2019, 85, E607-E608.	1.3	21
319	INNV-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS. Neuro-Oncology, 2019, 21, vi137-vi137.	1.2	21
320	CT-guided versus MR-guided radiotherapy: Impact on gastrointestinal sparing in adrenal stereotactic body radiotherapy. Radiotherapy and Oncology, 2022, 166, 101-109.	0.6	21
321	Clinical promise tempered by reality in the delivery of combined chemoradiation for common solid tumors. Seminars in Radiation Oncology, 2003, 13, 3-12.	2.3	20
322	Cost-effectiveness of prophylactic cranial irradiation with hippocampal avoidance in limited stage small cell lung cancer. Radiotherapy and Oncology, 2017, 122, 411-415.	0.6	20
323	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clinical Cancer Research, 2022, 28, 585-593.	7.2	20
324	Temozolomide-induced severe myelosuppression. Anti-Cancer Drugs, 2011, 22, 104-110.	1.4	19

#	Article	IF	Citations
325	The Changing Role of Whole-Brain Radiotherapy. JAMA Oncology, 2017, 3, 1021.	7.3	19
326	Integration of Systemic Therapy and Stereotactic Radiosurgery for Brain Metastases. Cancers, 2021, 13, 3682.	3.8	19
327	Management of solitary and multiple brain metastases from breast cancer. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 87-93.	0.2	19
328	Treatment of malignant gliomas: radiotherapy, chemotherapy and integration of new targeted agents. Expert Review of Neurotherapeutics, 2004, 4, 691-703.	2.8	18
329	Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1107-1115.	0.8	18
330	Patterns of treatment failure in infants with primitive neuroectodermal tumors who were treated on CCG-921: A phase III combined modality study. Pediatric Blood and Cancer, 2005, 45, 676-682.	1.6	18
331	Commissioning and Quality Assurance of RapidArc Radiotherapy Delivery System: In Regard to Ling et al. (Int J Radiat Oncol Biol Phys 2008;72;575â€“581): Absence of Data Does Not Constitute Proof; The Proof is in Tasting the Pudding. International Journal of Radiation Oncology Biology Physics, 2009, 75, 4-6.	0.8	18
332	Novel insights into the management of brain metastases. Current Opinion in Neurology, 2010, 23, 556-562.	3.7	18
333	Current practices of driving restriction implementation for patients with brain tumors. Journal of Neuro-Oncology, 2011, 103, 641-647.	3.0	18
334	Preradiation Chemotherapy for Adult High-risk Medulloblastoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 588-594.	1.3	18
335	Onco-metabolism: defining the prognostic significance of obesity and diabetes in women with brain metastases from breast cancer. Breast Cancer Research and Treatment, 2018, 172, 221-230.	2.5	18
336	Pretreatment Volume of MRI-Determined White Matter Injury Predicts Neurocognitive Decline After Hippocampal Avoidant Whole-Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology Radiation Therapy Oncology Group 0933. Advances in Radiation Oncology, 2019, 4, 579-586.	1.2	18
337	Treatment of WilmsÊ¼ Tumour. Drugs, 1991, 42, 766-780.	11.1	17
338	Linear accelerator configurations for radiosurgery. Seminars in Radiation Oncology, 1995, 5, 203-212.	2.3	17
339	Trastuzumab for Breast Cancerâ€“Related Carcinomatous Meningitis. Clinical Breast Cancer, 2002, 2, 316.	2.6	17
340	Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1122-1126.	0.8	17
341	Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations. Current Problems in Cancer, 2004, 28, 7-40.	2.1	17
342	A Comparison of Helical Tomotherapy to Circular Collimator-Based Linear-Accelerator Radiosurgery for the Treatment of Brain Metastases. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 388-394.	1.3	17

#	Article	IF	Citations
343	Radiation-induced brain damage, impact of Michael Robbinsâ€™ work and the need for predictive biomarkers. International Journal of Radiation Biology, 2014, 90, 742-752.	1.5	17
344	Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525. Neuro-Oncology, 2015, 17, 999-1006.	1.2	17
345	Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 75-81.	4.1	17
346	Repeat reirradiation of the spinal cord: multi-national expert treatment recommendations. Strahlentherapie Und Onkologie, 2018, 194, 365-374.	2.2	17
347	Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825). Neuro-Oncology, 2021, 23, 1125-1138.	1.2	17
348	Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance. Neuro-Oncology Advances, 2021, 3, vdab010.	0.7	17
349	Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of â‰¤6 brain metastases: a multi-institutional phase II trial. Journal of Neuro-Oncology, 2011, 105, 301-308.	3.0	16
350	Markov Model and Cost-Effectiveness Analysis of Bevacizumab in HER2-Negative Metastatic Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 480-485.	1.3	16
351	Strategies to Prevent Brain Metastasis in High-Risk Nonâ€“Small-Cell Lung Cancer: Lessons Learned From a Randomized Study of Maintenance Temozolomide Versus Observation. Clinical Lung Cancer, 2014, 15, 433-440.	2.7	16
352	Investigating Low-Dose Thoracic Radiation as a Treatment for COVID-19 Patients to Prevent Respiratory Failure. Radiation Research, 2020, 194, 1.	1.5	16
353	Assessment of patient-independent intrinsic error for a noninvasive frame for fractionated stereotactic radiotherapy. International Journal of Cancer, 2001, 96, 320-325.	5.4	15
354	Combined modality treatment for central nervous system malignancies. Seminars in Oncology, 2003, 30, 11-22.	2.3	15
355	Motexafin gadolinium: a novel radiosensitizer for brain tumors. Expert Opinion on Pharmacotherapy, 2009, 10, 2171-2180.	1.9	15
356	Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma. Medical Hypotheses, 2011, 76, 410-413.	1.5	15
357	Role of isocitrate dehydrogenase in glioma. Expert Review of Neurotherapeutics, 2011, 11, 1399-1409.	2.8	15
358	A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806). Journal of Neuro-Oncology, 2013, 111, 33-39.	3.0	15
359	What predicts early volumetric edema increase following stereotactic radiosurgery for brain metastases?. Journal of Neuro-Oncology, 2016, 127, 303-311.	3.0	15
360	What is the evidence for the clinical value of SBRT in cancer of the cervix?. Reports of Practical Oncology and Radiotherapy, 2018, 23, 574-579.	0.7	15

#	Article	IF	Citations
361	Effectiveness of Radiofrequency Ablation in the Treatment of Painful Osseous Metastases: A Correlation Meta-Analysis with Machine Learning Cluster Identification. Journal of Vascular and Interventional Radiology, 2020, 31, 1753-1762.	0.5	15
362	Access to Radiation Therapy: From Local to Global and Equality to Equity. JCO Global Oncology, 2022, , .	2.3	15
363	Stereotactic Body Radiation Therapy in Nonâ€“Small-Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 432-441.	1.3	14
364	Cognitive function testing in adult brain tumor trials: lessons from a comprehensive review. Expert Review of Anticancer Therapy, 2012, 12, 655-667.	2.6	14
365	Prophylactic Cranial Irradiation: Recent Outcomes and Innovations. CNS Oncology, 2014, 3, 219-230.	2.7	14
366	Whole-Brain Radiotherapy and Stereotactic Radiosurgery in Brain Metastases: What Is the Evidence?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e99-e104.	4.1	14
367	Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study. Journal of Neuro-Oncology, 2018, 140, 341-349.	3.0	14
368	Implementation Strategies to Increase Clinical Trial Enrollment in a Community-Academic Partnership and Impact on Hispanic Representation: An Interrupted Time Series Analysis. JCO Oncology Practice, 2022, 18, e780-e785.	2.8	14
369	Recurrent Malignant Gliomas Treated with Radiosurgery. Journal of Radiosurgery, 1999, 2, 119-125.	0.1	13
370	Title is missing!. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 273-279.	1.3	13
371	Potential for Radiation Therapy Technology Innovations to Permit Dose Escalation for Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2005, 7, 107-113.	2.7	13
372	Radiation Techniques in Neuro-Oncology. Neurotherapeutics, 2009, 6, 487-499.	4.7	13
373	Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stageÂI disease. Strahlentherapie Und Onkologie, 2017, 193, 515-524.	2.2	13
374	Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?. Translational Research, 2019, 208, 63-72.	5.2	13
375	Free Breathing versus Breath-Hold Scanning Beam Proton Therapy and Cardiac Sparing in Breast Cancer. International Journal of Particle Therapy, 2016, 3, 407-413.	1.9	13
376	Resection versus radiosurgery for patients with brain metastases. Future Oncology, 2007, 3, 95-102.	2.4	12
377	On the Estimation of the Location of the Hippocampus in the Context of Hippocampal Avoidance Whole Brain Radiotherapy Treatment Planning. Technology in Cancer Research and Treatment, 2009, 8, 425-432.	1.9	12
378	Clinical ramifications of â€œgenomic stagingâ€•of low-grade gliomas. Journal of Neuro-Oncology, 2016, 129, 195-199.	3.0	12

#	Article	IF	Citations
379	ACTR-32. NRG ONCOLOGY RTOG 1205: RANDOMIZED PHASE II TRIAL OF CONCURRENT BEVACIZUMAB AND RE-IRRADIATION VS. BEVACIZUMAB ALONE AS TREATMENT FOR RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi20-vi20.	1.2	12
380	Systematic evaluation and plan quality assessment of the LeksellÂ® gamma knifeÂ® lightning dose optimizer. Medical Dosimetry, 2022, 47, 70-78.	0.8	12
381	The Status of Stereotactic Radiosurgery for Cerebral Metastases in 1998. Journal of Radiosurgery, 1998, 1, 17-30.	0.1	11
382	Radiotherapy for brain tumors. Current Oncology Reports, 2000, 2, 438-444.	4.1	11
383	Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Journal of Neuro-Oncology, 2021, 155, 363-372.	3.0	11
384	Evaluation of the impact of pre-operative stereotactic radiotherapy on the acute changes in histopathologic and immune marker profiles of brain metastases. Scientific Reports, 2022, 12, 4567.	3.4	11
385	ONC201 (Dordaviprone) in Recurrent H3 K27Mâ€“Mutant Diffuse Midline Glioma. Journal of Clinical Oncology, 2024, 42, 1542-1552.	15.4	11
386	90Y Â· B72.3 Against pancreatic cancer: Dosimetric and biological analysis. International Journal of Radiation Oncology Biology Physics, 1990, 19, 627-631.	0.8	10
387	Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation. Lancet Oncology, The, 2018, 19, e366.	10.8	10
388	Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420. International Journal of Radiation Oncology Biology Physics, 2019, 103, 878-886.	0.8	10
389	Dose-Escalated Magnetic Resonance Imageâ€“Guided Abdominopelvic Reirradiation With Continuous Intrafraction Visualization, Soft Tissue Tracking, and Automatic Beam Gating. Advances in Radiation Oncology, 2022, 7, 100840.	1.2	10
390	Impact of molecular profiling on clinical trial design for glioblastoma. Current Oncology Reports, 2007, 9, 71-79.	4.1	9
391	In Regard to Sperduto et al. International Journal of Radiation Oncology Biology Physics, 2013, 86, 809-810.	0.8	9
392	Chemoradiation for Definitive, Preoperative, or Postoperative Therapy of Locally Advanced Non-Small Cell Lung Cancer. Cancer Journal (Sudbury, Mass), 2013, 19, 222-230.	2.0	9
393	International Medical Graduates in Radiation Oncology: Historical Trends and Comparison With Other Medical Specialties. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1102-1106.	0.8	9
394	Case report of visual biofeedback-driven, magnetic resonance-guided single-fraction SABR in breath hold for early stage nonâ€“small-cell lung cancer. Medical Dosimetry, 2021, 46, 247-252.	0.8	9
395	Genetic landscape of extreme responders with anaplastic oligodendroglioma. Oncotarget, 2017, 8, 35523-35531.	2.1	9
396	Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases. Frontiers in Oncology, 2021, 11, 780379.	2.9	9

#	Article	IF	Citations
397	Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data. Cancers, 2022, 14, 2020.	3.8	9
398	Zero Setup Margin Mask versus Frame Immobilization during Gamma KnifeÂ® Iconâ„¢ Stereotactic Radiosurgery for Brain Metastases. Cancers, 2022, 14, 3392.	3.8	9
399	Three-dimensional conformal radiotherapy for lung cancer: Promises and pitfalls. Current Oncology Reports, 2002, 4, 347-353.	4.1	8
400	Are More Aggressive Therapies Able to Improve Treatment of Locally Advanced Non-Small Cell Lung Cancer: Combined Modality Treatment?. Seminars in Oncology, 2005, 32, 25-34.	2.3	8
401	Combined Modality Approaches in the Management of Adult Glioblastoma. Frontiers in Oncology, 2011, 1, 36.	2.9	8
402	Potential of glyburide to reduce intracerebral edema in brain metastases. Expert Review of Neurotherapeutics, 2014, 14, 379-388.	2.8	8
403	Defining an Intermediate-risk Group for Low-grade Glioma: A National Cancer Database Analysis. Anticancer Research, 2019, 39, 2911-2918.	1.1	8
404	Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes. Neurosurgery, 2019, 84, 66-76.	1.3	8
405	Novel Radiation Approaches. Neurosurgery Clinics of North America, 2021, 32, 211-223.	1.8	8
406	A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas. Journal of Neuro-Oncology, 2021, 155, 297-306.	3.0	8
407	Stereotactic radiosurgery improves survival in malignant gliomas compared with the RTOG recursive partitioning analysis. International Journal of Radiation Oncology Biology Physics, 1994, 30, 164-165.	0.8	7
408	Phase I Trial of Intravenous Thymidine and Carboplatin in Patients With Advanced Cancer. Journal of Clinical Oncology, 1999, 17, 2922-2922.	15.4	7
409	Helical tomotherapy as a means of administering total or partial scalp irradiation: In regards to Bedford et al. (Int J Radiat Oncol Biol Phys 2005;62:1549â€“1558). International Journal of Radiation Oncology Biology Physics, 2006, 64, 1288-1289.	0.8	7
410	A phase I study of gemcitabine plus palliative radiation therapy for advanced lung cancer. Cancer Chemotherapy and Pharmacology, 2008, 63, 175-179.	2.4	7
411	Integrated phase II/III clinical trials in oncology: A case study. Clinical Trials, 2012, 9, 741-747.	1.8	7
412	AT-13 * R9802: PHASE III STUDY OF RADIATION THERAPY (RT) WITH OR WITHOUT PROCARBAZINE, CCNU, AND VINCRISTINE (PCV) IN LOW-GRADE QLIOMA: RESULTS BY HISTOLOGIC TYPE. Neuro-Oncology, 2014, 16, v11-v11.	1.2	7
413	Control versus cognition: the changing paradigm of adjuvant therapy for resected brain metastasis. Neuro-Oncology, 2018, 20, 2-3.	1.2	7
414	Stereotactic MR-guided online adaptive radiotherapy reirradiation (SMART reRT) for locally recurrent pancreatic adenocarcinoma: A case report. Medical Dosimetry, 2021, 46, 384-388.	0.8	7

#	Article	IF	Citations
415	Assessment of extracranial metastatic disease in patients with brain metastases: How much effort is needed in the context of evolving survival prediction models?. Radiotherapy and Oncology, 2021, 159, 17-20.	0.6	7
416	Anteriorly Oriented Beam Arrangements with Daily in Vivo Range Verification for Proton Therapy of Prostate Cancer: Rectal Toxicity Rates. International Journal of Particle Therapy, 2016, 2, 509-517.	1.9	7
417	Orbital metastasis of pituitary growth hormone secreting carcinoma causing lateral gaze palsy. , 2013, 4, 59.		7
418	Systematic review and meta-analysis of lung cancer brain metastasis and primary tumor receptor expression discordance. Discover Oncology, 2021, 12, 48.	2.2	7
419	Dedicated isotropic 3-D T1 SPACE sequence imaging for radiosurgery planning improves brain metastases detection and reduces the risk of intracranial relapse. Radiotherapy and Oncology, 2022, 173, 84-92.	0.6	7
420	A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors consortium report. Investigational New Drugs, 2003, 21, 429-433.	2.7	6
421	A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies. Lung Cancer, 2004, 44, 111-119.	2.0	6
422	Temozolomide as Prophylaxis for Brain Metastasis in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 732-733.	1.2	6
423	Recent Updates in the Treatment of Glioblastoma: Introduction. Seminars in Oncology, 2014, 41, S1-S3.	2.3	6
424	Identification of Patients Who Benefit From Bevacizumab in High-Grade Gliomaâ€"An Easy Question Turned Difficult: Treat the Scan or the Patient?. Journal of Clinical Oncology, 2016, 34, 1281-1282.	15.4	6
425	The Complexity of Managing Large Brain Metastasis. International Journal of Radiation Oncology Biology Physics, 2019, 104, 483-484.	0.8	6
426	Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. Neuro-Oncology Advances, 2020, 2, vdaa124.	0.7	6
427	Prevalence and Inpatient Hospital Outcomes of Malignancy-Related Ascites in the United States. American Journal of Hospice and Palliative Medicine, 2021, 38, 47-53.	1.5	6
428	Meta-Analysis of Survival and Development of a Prognostic Nomogram for Malignant Pleural Mesothelioma Treated with Systemic Chemotherapy. Cancers, 2021, 13, 2186.	3.8	6
429	Cross-sectional survey of patients, caregivers, and physicians on diagnosis and treatment of brain metastases. Neuro-Oncology Practice, 2021, 8, 662-673.	1.5	6
430	Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma. JCO Precision Oncology, 2021, 5, 1397-1407.	3.2	6
431	Hospitalization rates from radiotherapy complications in the United States. Scientific Reports, 2022, 12, 4371.	3.4	6
432	Treatment of glioblastoma using MRIdianÂ® A3i BrainTxâ„¢: Imaging and treatment workflow demonstration. Medical Dosimetry, 2023, 48, 127-133.	0.8	6

#	Article	IF	Citations
433	Radiosurgery for Single and Multiple Brain Metastases. , 2004, , 139-164.		5
434	Radiation Oncology Advances: An Introduction. Cancer Treatment and Research, 2008, 139, 1-4.	0.0	5
435	Radiographic Pneumonitis Patterns and Low Pulmonary Toxicity After Helical Tomotherapy. American Journal of Roentgenology, 2010, 194, W459-W459.	2.8	5
436	A Roundtable Discussion on the Clinical Challenges and Options for the Treatment of Glioblastoma: Introducing a Novel Modality, TTFields. Seminars in Oncology, 2013, 40, S2-S4.	2.3	5
437	Using Intensity-Modulated Radiotherapy to Spare the Kidney in a Patient with Seminoma and a Solitary Kidney: A Case Report. Tumori, 2013, 99, e38-e42.	1.1	5
438	The association between BMI and BSAâ€“temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525. Neuro-Oncology Practice, 2019, 6, 473-478.	1.5	5
439	Regression of Intracranial Meningiomas Following Treatment with Cabozantinib. Current Oncology, 2021, 28, 1537-1543.	2.3	5
440	Systematic review and meta-analysis of PD-L1 expression discordance between primary tumor and lung cancer brain metastasis. Neuro-Oncology Advances, 2021, 3, vdab166.	0.7	5
441	Pulsed-Reduced Dose Rate (PRDR) Radiotherapy for Recurrent Primary Central Nervous System Malignancies: Dosimetric and Clinical Results. Cancers, 2022, 14, 2946.	3.8	5
442	Thorotrast-associated Oropharyngeal Hemorrhage: Treatment by Means of Carotid Occlusion with Use of Flow Arrest and Fibered Coils. Journal of Vascular and Interventional Radiology, 1996, 7, 709-712.	0.5	4
443	Multiple daily fractionation radiotherapy schedules in lung cancer. Current Oncology Reports, 2001, 3, 179-184.	4.1	4
444	What is the appropriate primary end point for clinical trials for patients with brain metastases? In Response to Drs. Burri and Asher. International Journal of Radiation Oncology Biology Physics, 2002, 53, 1394.	0.8	4
445	Gangliogliomasâ€”what is the appropriate management strategy?. Nature Reviews Neurology, 2010, 6, 190-191.	10.0	4
446	Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM). Biomarker Research, 2013, 1, 29.	7.0	4
447	High prevalence of hepatitis B non-immunity in paediatric non-alcoholic fatty liver disease patients. Digestive and Liver Disease, 2014, 46, 760-761.	0.9	4
448	ATCT-09IDH1 R132H MUTATIONS IN NRG ONCOLOGY/RTOG 9802: PHASE III STUDY OF RADIATION THERAPY (RT) ALONE VS RT PLUS PROCARBAZINE, CCNU, AND VINCRISTINE (PCV) IN PATIENTS WITH LOW GRADE GLIOMA (LGG). Neuro-Oncology, 2015, 17, v3.1-v3.	1.2	4
449	Radiation therapy alone versus radiation therapy plus radiofrequency ablation/vertebral augmentation for spine metastasis: study protocol for a randomized controlled trial. Trials, 2020, 21, 964.	1.7	4
450	Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, 75-81.	4.1	4

#	Article	IF	Citations
451	An overview of modern proton therapy. Chinese Clinical Oncology, 2016, 5, 48-48.	1.3	4
452	Factors associated with unplanned readmissions and costs following resection of brain metastases in the United States. Scientific Reports, 2021, 11, 22152.	3.4	4
453	Comparison of Methods for Response Analysis of Central Nervous System Neoplasms. Journal of Radiosurgery, 1999, 2, 153-161.	0.1	3
454	Accelerated hypofractionation. International Journal of Radiation Oncology Biology Physics, 2005, 61, 299-300.	0.8	3
455	Strategies for enhanced radiation delivery in patients with lung cancer. Expert Opinion on Drug Delivery, 2005, 2, 103-113.	5.1	3
456	In response to â€œThe distribution of brain metastases in the perihippocampal region (Regarding Gondi et) Tj ETQq0 0 0 rgBT /Overlock	0.6	3
457	In Regard to Yamamoto et al. International Journal of Radiation Oncology Biology Physics, 2012, 84, 875-876.	0.8	3
458	ATCT-08THE IMPACT OF EXTENDED ADJUVANT TEMOZOLOMIDE IN NEWLY-DIAGNOSED GLIOBLASTOMA: A SECONDARY ANALYSIS OF EORTC AND NRG ONCOLOGY/RTOG. Neuro-Oncology, 2015, 17, v2.4-v2.	1.2	3
459	ATCT-27NRG ONCOLOGY/RTOG 0929: A RANDOMIZED PHASE I/II STUDY OF ABT-888IN COMBINATION WITH TEMOZOLOMIDE IN RECURRENT TEMOZOLOMIDE RESISTANT GLIOBLASTOMA. Neuro-Oncology, 2015, 17, v7.3-v7.	1.2	3
460	In Regard to Badiyan etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 91, 453-454.	0.8	3
461	Pathologic deposition of non-amyloid immunoglobulin in the brain leading to mass effect and neurological deficits. Journal of Clinical Neuroscience, 2016, 30, 143-145.	1.6	3
462	Consolidative Whole-Brain Radiation Therapy Versus Autologous Stem Cell Transplant for Primary Central Nervous System Lymphoma: A Large Dose of Perspective and Perhaps a Lower Dose of Radiation Are in Order. International Journal of Radiation Oncology Biology Physics, 2018, 102, 59-60.	0.8	3
463	ACTR-34. INTEGRATED CLINICAL EXPERIENCE WITH ONC201 IN PREVIOUSLY-TREATED H3 K27M-MUTANT GLIOMA PATIENTS. Neuro-Oncology, 2018, 20, vi19-vi19.	1.2	3
464	A risk model for prediction of 30-day readmission rates after surgical treatment for colon cancer. International Journal of Colorectal Disease, 2020, 35, 1529-1535.	2.3	3
465	Early imaging marker of progressing glioblastoma: a window of opportunity. Journal of Neuro-Oncology, 2020, 148, 629-640.	3.0	3
466	Expanding the Utilization of Rectal Spacer Hydrogel for Larger Prostate Glands (>80 cc): Feasibility and Dosimetric Outcomes. Advances in Radiation Oncology, 2021, 6, 100651.	1.2	3
467	Impact of MRI timing on tumor volume and anatomic displacement for brain metastases undergoing stereotactic radiosurgery. Neuro-Oncology Practice, 2021, 8, 674-683.	1.5	3
468	Relationship between insurance status and interhospital transfers among cancer patients in the United States. BMC Cancer, 2022, 22, 121.	2.6	3

#	Article	IF	Citations
469	Surgically targeted radiation therapy (STaRT) for recurrent brain metastases: Initial clinical experience. Brachytherapy, 2023, 22, 872-881.	0.8	3
470	In reply to Dr. Kondziolka et al. International Journal of Radiation Oncology Biology Physics, 2005, 62, 615-616.	0.8	2
471	Reply to M.C. Chamberlain et al. Journal of Clinical Oncology, 2012, 30, 3316-3317.	15.4	2
472	Reply to M.C. Chamberlain. Journal of Clinical Oncology, 2014, 32, 1634-1635.	15.4	2
473	RTRB-05DEFINING THE ROLE OF PROPHYLACTIC CRANIAL IRRADIATION IN NSCLC: A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE WORLD'S LITERATURE. Neuro-Oncology, 2015, 17, v196.1-v196.	1.2	2
474	ATCT-22NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA. Neuro-Oncology, 2015, 17, v6.2-v6.	1.2	2
475	Should we irradiate a brain tumor in a patient with parkinsonism? A case report and literature review. Practical Radiation Oncology, 2015, 5, e327-e335.	2.1	2
476	Reply to F. Felix et al and M.F. Fay et al. Journal of Clinical Oncology, 2016, 34, 3107-3108.	15.4	2
477	Inpatient Palliative Care Use Among Critically Ill Brain Metastasis Patients in the United States. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 806-812.	1.3	2
478	Extreme hypofractionation for newly diagnosed glioblastoma: rationale, dose, techniques, and outcomes. Neuro-Oncology, 2020, 22, 1062-1064.	1.2	2
479	Stereotactic Irradiation. , 2012, , 331-343.		2
480	Prognostic value of H-MLH1 after adjusting for RPA class in GBM patients. Frontiers in Bioscience - Elite, 2011, E3, 1182-1191.	1.8	2
481	Endobronchial brachytherapy: Wither prescription point. International Journal of Radiation Oncology Biology Physics, 1992, 23, 251.	0.8	1
482	In response to Dr. PeÃ±agarÃcano. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1274-1275.	0.8	1
483	In Response to Dr. Knisely and Colleagues. International Journal of Radiation Oncology Biology Physics, 2011, 79, 958.	0.8	1
484	Proton Beam Therapy Basics. Journal of the American College of Radiology, 2015, 12, 1204-1206.	1.8	1
485	ATNT-10DOES VALPROIC ACID IMPROVE SURVIVAL IN GLIOBLASTOMA? A META-ANALYSIS OF RANDOMIZED TRIALS IN NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2015, 17, v12.2-v12.	1.2	1
486	Society for Neuro-Oncology 2014 annual meeting updates on central nervous system metastases. Neuro-Oncology Practice, 2015, 2, 57-61.	1.5	1

#	Article	IF	Citations
487	ATCT-12RESULTS OF NRG ONCOLOGY/RTOG 9813- A PHASE III RANDOMIZED STUDY OF RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) VERSUS RT AND NITROSOUREA (NU) THERAPY FOR ANAPLASTIC ASTROCYTOMA (AA). Neuro-Oncology, 2015, 17, v3.4-v3.	1.2	1
488	Basic principles of brain tumor radiotherapy. , 2019, , 245-262.		1
489	WHO II and III Gliomas. , 2019, , 217-236.		1
490	Effect of Postoperative Radiation Therapy Timing on Survival in Pediatric and Young Adult Ependymoma. Advances in Radiation Oncology, 2021, 6, 100691.	1.2	1
491	Radiation for Brain Metastases. Cancer Treatment and Research, 2007, 136, 91-115.	0.0	1
492	Combined Chemoradiotherapy Advances. Cancer Treatment and Research, 2008, , 277-301.	0.0	1
493	A Comprehensive Analysis of a Prospective Multidisciplinary Peer Review Process Before Radiation Therapy Simulation. Practical Radiation Oncology, 2021, 11, e366-e375.	2.1	1
494	Evaluation of a prospective radiation oncology departmental team review process using standardized simulation directives. Radiotherapy and Oncology, 2022, 170, 102-110.	0.6	1
495	RONC-13. Change in hippocampus volume as a function of radiation dose: Results from a prospective trial with standardized imaging and morphometric evaluation. Neuro-Oncology, 2022, 24, i179-i179.	1.2	1
496	Endobronchial irradiation: Is HDR better?. International Journal of Radiation Oncology Biology Physics, 1990, 19, 1629.	0.8	0
497	Response to editorial by Drs. Lanciano and corn. International Journal of Radiation Oncology Biology Physics, 1993, 27, 991.	0.8	0
498	Glioblastoma multiforme: â€œwho should receive stereotactic boost therapy?â€• International Journal of Radiation Oncology Biology Physics, 1994, 30, 746.	0.8	0
499	Manpower issues and training program directions in radiation oncology. International Journal of Radiation Oncology Biology Physics, 1996, 34, 970.	0.8	0
500	214 Endobronchial and endoesophageal high dose rate brachytherapy for malignant airway and digestive tract obstructions. International Journal of Radiation Oncology Biology Physics, 1997, 39, 123.	0.8	0
501	1021 Optic nerve tolerance to single and fractionated radiation simulating radiosurgery: A rabbit model using visual evoked potentials, fundoscopy and histology. International Journal of Radiation Oncology Biology Physics, 1997, 39, 226.	0.8	0
502	On â€œStereotactic Radiosurgery for Patients with Single Brain Metastasisâ€•(Cho et al., This Issue). Journal of Radiosurgery, 1998, 1, 87-88.	0.1	0
503	E-53. Helical tomotherapy: An innovative technological radiation therapeutic approach for lung cancer. Lung Cancer, 2003, 41, S67-S68.	2.0	0
504	In response to Drs. Vordermark and KÃ¶lbl. International Journal of Radiation Oncology Biology Physics, 2005, 62, 297.	0.8	0

#	Article	IF	Citations
505	B1-07: Decreased neurocognitive progression with Motexafin Gadolinium (MGd) plus Whole Brain Radiation Therapy (WBRT) in non-small cell lung cancer (NSCLC) patients with brain metastases: pooled analysis of two randomized phase 3 trials. Journal of Thoracic Oncology, 2007, 2, S335-S336.	1.2	0
506	PD5-2-8: Predictors of survival for non-small-cell lung cancer patients with brain metastases treated with whole brain radiation therapy: pooled data from two randomized trials. Journal of Thoracic Oncology, 2007, 2, S478.	1.2	0
507	In Reply to Drs. Nieder and Molls. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1619.	0.8	0
508	In Reply to Drs. Weltman and Brandt. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1292-1293.	0.8	0
509	Treatment-Related Pneumonitis and Acute Esophagitis in Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy and Helical Tomotherapy: In Regard to Song etÂal.. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1281.	0.8	0
510	Brain Metastases. Medical Radiology, 2010, , 209-223.	0.0	0
511	Reply to Drs. Mulvenna and Holt. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1194-1195.	0.8	0
512	Pro: Lung Cancer in 2011: A Time for Optimism and Investment in New Approaches and Technologies with a Commitment to Produce Evidence-Based Data. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1231-1234.	6.6	0
513	Advances in Radiation Oncology of Lung Cancer. Medical Radiology, 2011, , 725-733.	0.0	0
514	In regards to Kirby et al . â€œPhysics strategies for sparing neural stem cells during whole-brain radiation treatments,â€•[Med. Phys. 38, 5338 (2011)]. Medical Physics, 2012, 39, 1677-1678.	2.9	0
515	NCO-14PRE-TREATMENT HIPPOCAMPAL VOLUME PREDICTS NEUROCOGNITIVE FUNCTION (NCF) FOR PATIENTS TREATED WITH HIPPOCAMPAL AVOIDANCE WHOLE BRAIN RADIOTHERAPY (HA-WBRT) FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY/RTOG 0933. Neuro-Oncology, 2015, 17, v149.1-v149.	1.2	0
516	BMET-20RTOG1119 PHASE II RANDOMIZED STUDY OF WHOLE BRAIN RADIOTHERAPY WITH CONCURRENT LAPATINIB IN PATIENTS WITH BRAIN METASTASIS FROM Her2-POSITIVE BREAST CANCER: A COLLABORATIVE STUDY OF NRG AND KROG (NCT01622868). Neuro-Oncology, 2015, 17, v49.2-v49.	1.2	0
517	RTRB-03SHORT DELAY IN INITIATION OF RADIOTHERAPY WITH CONCURRENT CHEMOTHERAPY FOR GLIOBLASTOMA: A SECONDARY ANALYSIS OF NRG ONCOLOGY/RTOG 0525 AND 0825. Neuro-Oncology, 2015, 17, v195.3-v195.	1.2	0
518	OP02ADOLESCENT/YOUNG ADULT MEDULLOBLASTOMA: TIME FOR A CHANGE IN MANAGEMENT STRATEGY. Neuro-Oncology, 2015, 17, viii16.2-viii16.	1.2	0
519	ATCT-29INVESTIGATING THE EFFECT OF REIRRADIATION OR SYSTEMIC THERAPY IN PATIENTS WITH GBM AFTER TUMOR PROGRESSION: A SECONDARY ANALYSIS OF THE NRG ONCOLOGY/RTOG 0525. Neuro-Oncology, 2015, 17, v8.1-v8.	1.2	0
520	RTRB-14TREATMENT RECOMMENDATIONS FOR ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA LACK WORLDWIDE CONSENSUS. Neuro-Oncology, 2015, 17, v198.2-v198.	1.2	0
521	Whole-Brain Radiotherapy for Brain Metastases: Is the Therapeutic Window Enlarging?. , 2015, , 41-56.		0
522	Reply to M.C. Chamberlain. Journal of Clinical Oncology, 2015, 33, 1986-1986.	15.4	0

#	Article	IF	Citations
523	Reply to M.C. Chamberlain. Journal of Clinical Oncology, 2016, 34, 4057-4057.	15.4	0
524	Future Directions for Tumor Treating Fields. , 2016, , 117-126.		0
525	Lung Cancer. , 2017, , 349-384.		0
526	P2.06-034 METIS: A Phase 3 Study of Radiosurgery with TTFields for 1-10 Brain Metastases from NSCLC. Journal of Thoracic Oncology, 2017, 12, S1092-S1093.	1.2	0
527	Medulloblastoma in Adults. , 2017, , 917-938.		0
528	Radiation Therapy in the Treatment of Low Grade Gliomas. , 2017, , 579-594.		0
529	State of the art: the evolving role of RT in combined modality therapy for GBM. Journal of Neuro-Oncology, 2017, 134, 477-478.	3.0	0
530	Brain Metastases in Lung Cancer With Targetable Mutationsâ€"Reply. JAMA Oncology, 2018, 4, 422.	7.3	0
531	Postoperative Management of Resected Brain Metastases: When Can Radiotherapy Be Deferred?. Journal of Clinical Oncology, 2018, 36, 3277-3281.	15.4	0
532	Radiotherapy innovations to optimize brain metastases control. Neuro-Oncology, 2020, 22, 1715-1717.	1.2	0
533	Die Rosenburg und der Kriegsverbrecher: Der Fall Max Merten. , 2021, , 123-154.		0
534	RADI-11. Evaluating the Tissue Effects of Dose-escalated Pre-operative Stereotactic Radiotherapy for Resectable Brain Metastasis. Neuro-Oncology Advances, 2021, 3, iii20-iii20.	0.7	0
535	OTHR-07. Systematic Review and Meta-analysis of Lung Cancer Brain Metastasis and Primary Tumor PD-L1 Expression Discordance. Neuro-Oncology Advances, 2021, 3, iii15-iii16.	0.7	0
536	Basic Concepts Underlying Radiation Therapy. , 2005, , 70-74.		0
537	Advances in the Treatment of Brain Metastases. Translational Medicine Series, 2007, , 207-230.	0.0	0
538	Stereotactic Body Radiation Therapy: Fractionated Radiation Therapy Perspective. , 2008, , 635-642.		0
539	Cost-Effectiveness and Quality of Life. , 2008, , 663-671.		0
540	Dose-Escalated High-Precision Radiotherapy: a Method to Overcome Variations in Biology and Radiosensitivity Limiting the Success of Conventional Approaches?. Medical Radiology, 2009, , 335-346.	0.0	0

#	Article	IF	Citations
541	Context for Protons as Adjunctive Therapy in Neovascular Age-Related Macular Degeneration: A Review. International Journal of Particle Therapy, 2016, 2, 555-569.	1.9	0
542	Intracranial Tumors. , 2022, , 177-199.		0
543	Optimizing the Radiotherapy Treatment Planning Process for Glioblastoma. Neuro-Oncology Practice, 0, , .	1.5	0
544	Rethinking Classification and Categorization of Resection Extent and its Impact on Patient Survival in Glioblastoma: Was Walter Dandy Ahead of His Time?. Neuro-Oncology, 0, , .	1.2	0
545	Dosimetric comparison of magnetic resonance-guided radiation therapy, intensity-modulated proton therapy and volumetric-modulated arc therapy for distal esophageal cancer. Medical Dosimetry, 2024, 49, 121-126.	0.8	0
546	Accelerated Hypofractionated Magnetic Resonance Guided Adaptive Radiation Therapy for Ultracentral Lung Tumors. Tomography, 2024, 10, 169-180.	1.9	0
547	Clinical application of an institutional fractionated stereotactic radiosurgery (FSRS) program for brain metastases delivered with MRIdianâ“‡ BrainTxâ„¢. Medical Dosimetry, 2024, , .	0.8	0
548	Proton Therapy: Current Status and Controversies. JCO Oncology Practice, 2024, 20, 747-749.	2.8	0
549	Multidisciplinary Management of Isocitrate Dehydrogenaseâ€“Mutated Gliomas in a Contemporary Molecularly Defined Era. Journal of Clinical Oncology, 2024, 42, 2588-2598.	15.4	0
550	Surgically targeted radiation therapy versus stereotactic radiation therapy: A dosimetric comparison for brain metastasis resection cavities. Brachytherapy, 2024, , .	0.8	0